A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-κ B pathway

Molecular Pharmacology

Volumn 75, Issue 4, 2009, Pages 812-819

  Zhu, Wenbo ^a   Ou, Yanqiu ^a   Li, Yan ^a   Xiao, Ru ^a   Shu, Minfeng ^a   Zhou, Yuehan ^a   Xie, Jun ^a   He, Songmin ^a   Qiu, Pengxin ^a   Yan, Guangmei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; HISTONE ACETYLTRANSFERASE PCAF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; TRIPTOLIDE; UROKINASE; VASCULOTROPIN;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID CARCINOMA;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CELL LINE, TUMOR; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EPOXY COMPOUNDS; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHENANTHRENES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRIPTERYGIUM;

EID: 63849258626     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.052605     Document Type: Article

References (40)

1. Aggarwal BB(2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203208.
2. Baldwin AS Jr(1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649-683.
3. Carmeliet P and Jain RK(2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
4. Chan EW, Cheng SC, Sin FW, and Xie Y(2001) Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol Lett 122:81-87.
5. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, Ross JA, and Rosen GD(2001) Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 276:2221-2227.
6. Chen BJ(2001) Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 42:253-265.
7. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, and Alitalo K(1997) Genomic organization ofhuman and mouse genes for vascular endothelial growth factor C. J Biol Chem 272:25176 -25183.
8. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X, and Jiang BH(2007) Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carci-nogenesis 28:858-864.
9. Ferrara N and Alitalo K(1999) Clinical applications ofangiogenic growth factors and their inhibitors. Nat Med 5:1359-1364.
10. Ferrara N, Gerber HP, and LeCouter J(2003) The biology ofVEGF and its receptors. Nat Med 9:669-676.
11. Ferrara N, Hillan KJ, and Novotny W(2005) Bevacizumab(Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Com-mun 333:328-335.
12. Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, and Rosen GD(2003) PG490 -88,a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2:855-862.
13. Gerber HP(2003) Anti-angiogenesis: biology is the foundation for therapy. Drug Discov Today 8:344 -346.
14. Hicklin DJ and Ellis LM(2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027.
15. Hoffmann A, Levchenko A, Scott ML, and Baltimore D(2002) The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298:1241-1245.
16. Huang S, Pettaway CA, Uehara H, Bucana CD, and Fidler IJ(2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197.
17. Huang S, Robinson JB, Deguzman A, Bucana CD, and Fidler IJ(2000) Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60:5334-5339.
18. Jain RK, Duda DG, Clark JW, and Loeffler JS(2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40.
19. Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, Yang D, and Lam SK(2001) Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 20:8009 -8018.
20. Karin M(2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436.
21. Kiviharju TM, Lecane PS, Sellers RG, and Peehl DM(2002) Antiproliferative and proapoptotic activities of triptolide(PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 8:2666 -2674.
22. Kong D, Li Y, Wang Z, Banerjee S, and Sarkar FH(2007) Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67:3310 -3319.
23. Lee KY, Chang W, Qiu D, Kao PN, and Rosen GD(1999) PG490(triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 274:13451-13455.
24. Liu Q, Chen T, Chen G, Shu X, Sun A, Ma P, Lu L, and Cao X(2007) Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappaB pathways. Mol Immunol 44:2686-2696.
25. Lou YJ and Jin J(2004) Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 45:373-376.
26. Mareel M and Leroy A(2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337-376.
27. Mattioli I, Geng H, Sebald A, Hodel M, Bucher C, Kracht M, and Schmitz ML(2006) Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon. J Biol Chem 281:6175-6183.
28. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, and Goellner JR(2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028 -1034.
29. Neff RL, Farrar WB, Kloos RT, and Burman KD(2008) Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37:525-538.
30. Pasieka JL(2003) Anaplastic thyroid cancer. Curr Opin Oncol 15:78-83.
31. Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM, and Saluja AK(2007) Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 67:9407-9416.
32. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, et al.(1999) Antivascular endothelial growth factor receptor(fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209 -5218.
33. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC, and Kao PN(1999) Immunosuppressant PG490(triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB tran-scriptional activation. J Biol Chem 274:13443-13450.
34. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, and Ribatti D(2006) Vascular endothelial growth factor(VEGF) as a target of bevacizumab in cancer:from the biology to the clinic. Curr Med Chem 13:1845-1857.
35. Schmitt M, Horbach A, Kubitz R, Frilling A, and Haussinger D(2004) Disruption of hepatocellular tight junctions by vascular endothelial growth factor(VEGF): a novel mechanism for tumor invasion. J Hepatol 41:274-283.
36. Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, and Shedd DP(1995) Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 17:41-48.
37. Weis S, Cui J, Barnes L, and Cheresh D(2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167:223-229.
38. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, and Zhang L(2003) Triptolide inhibits the growth and metastasis ofsolid tumors. Mol Cancer Ther 2:65-72.
39. Zhong H, May MJ, Jimi E, and Ghosh S(2002) The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9:625-636.
40. Zhong H, Voll RE, and Ghosh S(1998) Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1:661-671.